CSIMarket
 


Icagen, Inc.  (ICGND)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

ICGND's Operating Income Growth by Quarter and Year

Icagen,'s Operating Income results by quarter and year




ICGND Operating Income (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter December - -2.69 -1.35 -0.15
III Quarter September -2.01 -1.17 -1.20 -1.07
II Quarter June -2.55 -1.57 -1.64 -1.03
I Quarter March -1.75 -3.07 -0.66 -0.96
FY   -6.31 -8.50 -4.85 -3.21



ICGND Operating Income third quarter 2019 Y/Y Growth Comment
Icagen, Inc. in the third quarter 2019 recorded Operating Loss of $ -2.01 millions.

According to the results reported in the third quarter 2019, Icagen, Inc. achieved the best Operating Income growth in Medical Laboratories industry. While Icagen, Inc.' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2019.

Explain Operating Income growth


ICGND Operating Income ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Icagen,'s third quarter 2019 Operating Income $ -2.01 millions ICGND's Income Statement
Icagen,'s third quarter 2018 Operating Income $ -1.17 millions Quarterly ICGND's Income Statement
New: More ICGND's historic Operating Income Growth >>


ICGND Operating Income (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Icagen,'s Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICGND's III. Quarter Q/Q Operating Income Comment
Even if Icagen, Inc. in the III. Quarter 2019 showed Operating Loss of $ -2.01 millions, management point out, that this are slight up side in contrast to the -2.55 millions in the second quarter.

Within Medical Laboratories industry Icagen, Inc. achieved highest sequential Operating Income growth. While Icagen,'s Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ICGND's III. Quarter Q/Q Operating Income Comment
Despite the fact, that Icagen, Inc. in the III. Quarter 2019 revealed Operating Loss of $ -2.01 millions, some analyst point out, that those numbers are improvement relative to the -2.55 millions in the second quarter.

Within Medical Laboratories industry Icagen, Inc. achieved highest sequential Operating Income growth. While Icagen,'s Operating Income growth quarter on quarter, overall rank is .


Icagen,'s 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2019)
12 Months Ending
(Jun 30 2019)
12 Months Ending
(Mar 31 2019)
12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
Cumulative Operating Income 12 Months Ending $ -9.00 $ -8.16 $ -7.18 $ -8.50 $ -7.17
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Icagen, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Sep 30 2019 period.
The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -8.16 millions in TTM ending quarter Jun 30 2019 and $ -7.19541 millions from the TTM period ending Sep 30 2018.

Icagen, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Icagen, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -9 millions in the Sep 30 2019 period.
The results are worsening as the cumulative Operating Loss is inflating from $ -8.16 millions in the twelve months ending a quarter before and $ -7.19541 millions for the twelve months ending in the quarter Sep 30 2018.

Icagen, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Medical Laboratories Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ICGND's Operating Income Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ICGND's Competitors
Operating Income Growth for Icagen,'s Suppliers
Operating Income Growth for ICGND's Customers

You may also want to know
ICGND's Annual Growth Rates ICGND's Profitability Ratios ICGND's Asset Turnover Ratio ICGND's Dividend Growth
ICGND's Roe ICGND's Valuation Ratios ICGND's Financial Strength Ratios ICGND's Dividend Payout Ratio
ICGND's Roa ICGND's Inventory Turnover Ratio ICGND's Growth Rates ICGND's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2019
Staar Surgical Company110.61%$ 110.613 millions
Lifeloc Technologies Inc 108.47%$ 108.466 millions
Semler Scientific Inc 101.23%$ 101.229 millions
Lifevantage Corp94.71%$ 94.713 millions
Haemonetics Corporation90.75%$ 90.746 millions
Conmed Corporation81.73%$ 81.731 millions
Syneos Health Inc 74.41%$ 74.405 millions
Iradimed Corporation73.94%$ 73.941 millions
Vanda Pharmaceuticals Inc 72.61%$ 72.614 millions
Koru Medical Systems Inc70.81%$ 70.812 millions
Nuvasive Inc69.80%$ 69.796 millions
Catalent Inc 68.63%$ 68.627 millions
Neurocrine Biosciences Inc 65.86%$ 65.856 millions
Genomic Health Inc61.98%$ 61.983 millions
Protokinetix Incorporated59.19%$ 59.193 millions
Bio rad Laboratories Inc 58.40%$ 58.401 millions
Zomedica Corp 54.16%$ 54.165 millions
Fonar Corporation50.79%$ 50.786 millions
Msa Safety Incorporated49.02%$ 49.024 millions
Alexion Pharmaceuticals Inc 47.80%$ 47.797 millions
Tenax Therapeutics Inc 45.44%$ 45.439 millions
Corcept Therapeutics Inc43.69%$ 43.689 millions
Teleflex Incorporated43.26%$ 43.257 millions
Anika Therapeutics Inc 40.55%$ 40.546 millions
Carlisle Companies Incorporated36.43%$ 36.429 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com